Evidence map›Paper›PMID 40765207›Full record

ArticleBiomolecules & therapeutics2025

Inhibitory Effect of a Novel Non-Steroidal AMPamide on Inflammation and Sebogenesis by Suppressing TLR4 and TLR6-Mediated Signaling Pathway.

Myo Hyeon Park, Yu Ra Jung, Eun Bi Choi, Bu-Mahn Park, Jeonghwan Hwang, Miyoung Park

Abstract read
In one paragraph

Article in Biomolecules & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Myo Hyeon ParkCRID Center, Neopharm Co., Ltd., Daejeon 34037, Republic of Korea.
Yu Ra JungCRID Center, Neopharm Co., Ltd., Daejeon 34037, Republic of Korea.
Eun Bi ChoiCRID Center, Neopharm Co., Ltd., Daejeon 34037, Republic of Korea.
Bu-Mahn ParkCRID Center, Neopharm Co., Ltd., Daejeon 34037, Republic of Korea.
Jeonghwan HwangCRID Center, Neopharm Co., Ltd., Daejeon 34037, Republic of Korea.
Miyoung ParkCS&R Lab, UKON Solutions Co., Ltd., Gwacheon 13802, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder that primarily affects areas with increased sebaceous gland activity, and is characterized by erythematous scaly lesions.

Indexed as

Anti-inflammationKeratinocytesSebocytesSeborrheic dermatitisTLRs

Identifiers

PMID40765207
PMCPMC12408208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.